Janssen has submitted requests for approval in the U.S. and Europe for its investigational HCV protease inhibitor simeprevir as an addition to interferon-based therapy for people with genotype 1 or 4 chronic hepatitis C virus infection.
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4065-janssen-submits-approval-requests-for-new-hepatitis-c-drug-simeprevir
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4065-janssen-submits-approval-requests-for-new-hepatitis-c-drug-simeprevir
No comments:
Post a Comment